Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 May 10;23(16):4651–4661. doi: 10.1158/1078-0432.CCR-17-0152

Fig. 1B. Schematic presentation of the design and time schedule of the study.

Fig. 1B

A double-blind placebo-controlled biomarker trial was conducted in early stage breast cancer patients, treating patients with placebo or with propranolol and etodolac for 11 consecutive days, starting 5 days before surgery. Propranolol doses were increased on the day of surgery. Of the 38 patients recruited, one from each group self-withdraw before surgery. Blood samples were collected before drug initiation (T1), on the morning before surgery (T2), on the morning after surgery (T3), and several days after cessation of drug treatment (T4). Tumor tissue was collected during surgery.